Company name Trevena, Inc.
Stock symbol TRVN
Status Under Investigation

NEW YORK, October 11, 2018 – Bragar Eagel & Squire, P.C. is investigating potential claims against Trevena, Inc. (NASDQ: TRVN).  Our investigation concerns whether Trevena has violated the federal securities laws and/or engaged in other unlawful business practices.

On May 2, 2016, Trevena announced that it had “reached general agreement” with the FDA on key elements of its Phase 3 program for oliceridine (TRV130) and was “very pleased” with the outcome of its discussions with the FDA.

On October 9, 2018, minutes from the FDA’s April 28, 2016 meeting with Trevena were released and showed that the FDA: “did not agree with the proposed dosing in the Phase 3 studies”; “did not agree with the proposed primary endpoint”; and “did not agree with the proposed non-inferiority (NI) margin for comparing morphine to oliceridine.”

On this news, Trevena shares fell over 64%, closing at $1.07 on October 9, 2018.

If you purchased or otherwise acquired Trevena shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.

First name*

Last name*

City, state, ZIP code

Email address*

Daytime phone

Evening phone

Purchase Date

No. of Shares

Purchase Price

Purchase Date

No. of Shares

Purchase Price

Join action?

Call to provide more information: Tel: (212) 355-4648

Please list below any additional transactions in this security:

Additional comments

The submission of this form does not create an attorney-client relationship, nor any obligation on the part of Bragar Eagel & Squire, P.C., or you to file a legal action. Any information you submit will be maintained as confidential. If Bragar Eagel & Squire, P.C., in its sole discretion, believes that you might be an appropriate class representative, Bragar Eagel & Squire, P.C., will contact you to discuss the matter and to determine whether to establish an attorney client relationship.